[21] Within cells, cyanocobalamin is converted to methylcobalamin and 5- deoxyadenosylcobalamin, coenzymes that participate respectively in homocysteine remethylation to methionine and in the isomerization of methylmalonyl-CoA to succinyl CoA, reactions essential for DNA synthesis, erythropoiesis, and myelin maintenance
The specific site for administration may vary depending on factors such as individual preference, body mass, age, and any underlying medical conditions
Clin Gastroenterol Hepatol 2018
What the Research Says About Safety Clinical studies on AOD9604 indicate that the peptide is generally welltolerated: In human trials, no significant adverse effects were reported at doses up to 1 mg/day (safety summary) Unlike growth hormone therapies, AOD9604 does not meaningfully elevate IGF1 levels (human data), which may reduce the risk of unwanted growthrelated side effects
Obesity drugs in clinical development
the clinical relevance of this finding in humans is unknown, and in UK and EU prescribing information this is noted as a precaution rather than a formal contraindication but individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their doctor
